Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

852 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.
Ongaro E, Cremolini C, Rossini D, Corti F, Pagani F, Morelli L, Urbani L, Masi G, Sposito C, Filippi B, Borelli B, Zucchelli G, Moretto R, Boccaccino A, Solaini L, de Braud F, Mazzaferro V, Falcone A, Cucchetti A, Pietrantonio F. Ongaro E, et al. Among authors: pagani f. ESMO Open. 2019 May 9;4(2):e000496. doi: 10.1136/esmoopen-2019-000496. eCollection 2019. ESMO Open. 2019. PMID: 31231562 Free PMC article.
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer.
Randon G, Fucà G, Rossini D, Raimondi A, Pagani F, Perrone F, Tamborini E, Busico A, Peverelli G, Morano F, Niger M, Antista M, Corallo S, Saggio S, Borelli B, Zucchelli G, Milione M, Pruneri G, Di Bartolomeo M, Falcone A, de Braud F, Cremolini C, Pietrantonio F. Randon G, et al. Among authors: pagani f. Sci Rep. 2019 Feb 27;9(1):2858. doi: 10.1038/s41598-019-39525-3. Sci Rep. 2019. PMID: 30814645 Free PMC article. Clinical Trial.
Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study.
Cremolini C, Benelli M, Fontana E, Pagani F, Rossini D, Fucà G, Busico A, Conca E, Di Donato S, Loupakis F, Schirripa M, Lonardi S, Borelli B, Ongaro E, Eason K, Morano F, Casagrande M, Fassan M, Sadanandam A, de Braud F, Falcone A, Pietrantonio F. Cremolini C, et al. Among authors: pagani f. ESMO Open. 2019 Mar 8;4(2):e000489. doi: 10.1136/esmoopen-2019-000489. eCollection 2019. ESMO Open. 2019. PMID: 30962964 Free PMC article.
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis.
Rossini D, Germani MM, Pagani F, Pellino A, Dell'Aquila E, Bensi M, Liscia N, Moretto R, Boccaccino A, Prisciandaro M, Manglaviti S, Schirripa M, Vivolo R, Scartozzi M, Santini D, Salvatore L, Pietrantonio F, Loupakis F, Falcone A, Cremolini C. Rossini D, et al. Among authors: pagani f. Clin Colorectal Cancer. 2020 Sep;19(3):191-199.e6. doi: 10.1016/j.clcc.2020.03.009. Epub 2020 Apr 11. Clin Colorectal Cancer. 2020. PMID: 32466976
EGFR Amplification in Metastatic Colorectal Cancer.
Randon G, Yaeger R, Hechtman JF, Manca P, Fucà G, Walch H, Lee J, Élez E, Seligmann J, Mussolin B, Pagani F, Germani MM, Ambrosini M, Rossini D, Ratti M, Salvà F, Richman SD, Wood H, Nanjangud G, Gloghini A, Milione M, Bardelli A, de Braud F, Morano F, Cremolini C, Pietrantonio F. Randon G, et al. Among authors: pagani f. J Natl Cancer Inst. 2021 Nov 2;113(11):1561-1569. doi: 10.1093/jnci/djab069. J Natl Cancer Inst. 2021. PMID: 33825902 Free PMC article.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature.
Lombardi P, Rossini D, Crespi V, Germani MM, Bergamo F, Pietrantonio F, Santini D, Allegrini G, Daniel F, Pagani F, Antoniotti C, Zaniboni A, Conca V, Latiano TP, Boccaccino A, Passardi A, Tamburini E, Masi G, Di Maio M, Cremolini C. Lombardi P, et al. Among authors: pagani f. Cancer Treat Rev. 2022 Feb;103:102326. doi: 10.1016/j.ctrv.2021.102326. Epub 2021 Dec 23. Cancer Treat Rev. 2022. PMID: 35016085
Atypical RAS Mutations in Metastatic Colorectal Cancer.
Pietrantonio F, Yaeger R, Schrock AB, Randon G, Romero-Cordoba S, Rossini D, Fucà G, Ross JS, Kotani D, Madison R, Kim ST, Salvatore L, Raimondi A, Pagani F, Borelli B, Perrone F, Di Bartolomeo M, Miller VA, Ali SM, Lee J, Yoshino T, de Braud F, Falcone A, Hechtman JF, Cremolini C. Pietrantonio F, et al. Among authors: pagani f. JCO Precis Oncol. 2019 Dec;3:1-11. doi: 10.1200/PO.19.00136. JCO Precis Oncol. 2019. PMID: 35100719 Free PMC article.
Tumour mutational burden predicts resistance to EGFR/BRAF blockade in BRAF-mutated microsatellite stable metastatic colorectal cancer.
Randon G, Intini R, Cremolini C, Elez E, Overman MJ, Lee J, Manca P, Bergamo F, Pagani F, Antista M, Angerilli V, Ros Montaña FJ, Lavacchi D, Boccaccino A, Fucà G, Brich S, Cattaneo L, Fassan M, Pietrantonio F, Lonardi S. Randon G, et al. Among authors: pagani f. Eur J Cancer. 2022 Jan;161:90-98. doi: 10.1016/j.ejca.2021.11.018. Epub 2021 Dec 18. Eur J Cancer. 2022. PMID: 34933155
852 results